← All trials
NCT04478721
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2020
- Primary completion
- Sep 30, 2023
- Completion date
- Sep 30, 2023
- First posted
- Jul 21, 2020
- Last posted
- Sep 1, 2020
- Enrollment
- 334
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fundación Pública AndaluzaLead sponsor
- Hospital Universitario Virgen MacarenaOverall official - principal investigator
- Spanish Network for Research in Infectious DiseasesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.